journal article·2019-12Open access

Phenothiazine-based theranostic compounds for in vivo near-infared fluorescence imaging of β-amyloid plaques and inhibition of Aβ aggregation

YongLiang Li, Jing Cai, Longjia Yan, Wanzheng Zhang, Li Li, Zhiyun Du, YanXiong Fang, ChangZhi Dong, Bernard Meunier, Huixiong Chen

Dyes and Pigments· Volume 171

Abstract

Abstract A global burden of Alzheimer's disease (AD) has been growing over last decades. Evidence indicates that β-amyloid (Aβ) production and senile plaque deposition in the brain is causative in the onset of AD pathogenesis. It appears much earlier than cognitive decline and plays a key role in initiating and developing AD neuropathology. As such, there is an intense passion with discovering theranostic agents which make a significant impact in diagnostic and therapy. Herein, we report an investigation of novel phenothiazine-based compounds as promising potential theranostic agents for AD. Remarkably, they have exhibited a high binding affinity toward Aβ aggregates, a good biostability and a strong increase in their fluorescence intensity with blue shift when interacting with Aβ aggregates. Furthermore, they have been simultaneously applied to perform NIR in vivo imaging of β-amyloid plaques in double transgenic AD mouse model, to prevent self-aggregation of Aβ monomer from forming toxic oligmers and to reduce Aβ-induced toxicity of human neuroblastoma cells (SH-SY5Y).
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Alzheimer's disease research and treatments · Cholinesterase and Neurodegenerative Diseases · Tryptophan and brain disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (35)

Show source-provided references
1. Alzheimer disease therapy--moving from amyloid-β to tau10.1038/nrneurol.2013.223 ↗
2. Resolving controversies on the path to Alzheimer's therapeutics10.1038/nm.2460 ↗
3. NIA commentary: translational issues in Alzheimer's disease drug development10.1038/npp.2011.116 ↗
4. Perspectives on inhibiting β-amyloid aggregation through structure-based drug design10.1002/cmdc.201500215 ↗
5. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease10.2174/157488911796958002 ↗
6. Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease10.1080/15216540601047767 ↗
7. Amyloid beta -protein (Abeta) assembly: abeta 40 and Abeta 42 oligomerize through distinct pathways10.1073/pnas.222681699 ↗
8. Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease10.1038/aps.2011.14 ↗
9. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease10.1093/brain/awt362 ↗
10. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration10.1073/pnas.1017033108 ↗
11. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction10.1042/BST0351219 ↗
12. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo10.1093/brain/awn174 ↗
13. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease10.1016/j.molmed.2007.12.002 ↗
14. Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease10.2174/156720509790147070 ↗
15. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options10.2174/157015909787602823 ↗
16. Dysregulation of calcium in Alzheimer's disease10.55782/ane-2003-1465 ↗
17. Bolognesi · 2013
18. Alzheimer's disease: the challenge of the second century10.1126/scitranslmed.3002369 ↗
19. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics10.1126/science.1072994 ↗
20. Amyloid beta: structure, biology and structure-based therapeutic development10.1038/aps.2017.28 ↗
21. Toward a rational design to regulate β-amyloid fibrillation for Alzheimer's disease treatment10.1021/acschemneuro.7b00477 ↗
22. Optical and opto-acoustic interventional imaging10.1007/s10439-011-0501-4 ↗
23. Fluorescence molecular tomography: principles and potential for pharmaceutical research10.3390/pharmaceutics3020229 ↗
24. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe10.1038/nbt1085 ↗
25. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers10.1002/anie.200500845 ↗
26. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits10.1021/ja9047043 ↗
27. BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques10.1021/cn3000058 ↗
28. Development of phenothiazine-based theranostic compounds that act both as inhibitors of β-amyloid aggregation and as imaging probes for amyloid plaques in Alzheimer's disease10.1021/acschemneuro.6b00380 ↗
29. Validation of the general purpose tripos 5.2 force field10.1002/jcc.540100804 ↗
30. Polarisation nucleaire induite chimiquement: etude comparative de la decomposition thermique et photochimique de peroxydes d'acyle benzoyle10.1016/0040-4020(80)80168-2 ↗
31. Charge distribution from molecular topology and orbital electronegativity
32. Unraveling the photoluminescence response of light-switching ruthenium(II) complexes bound to amyloid-β10.1021/ja404850u ↗
33. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo10.1074/jbc.M404751200 ↗
34. Binding of Congo red to amyloid protofibrils of the Alzheimer Aβ(9-40) peptide probed by molecular dynamics simulations10.1016/j.bpj.2012.07.008 ↗
35. Dual binding modes of Congo red to amyloid protofibril surface observed in molecular dynamics simulations10.1021/ja0662772 ↗